Sectra has entered into an agreement to acquire Oxipit, a developer of artificial intelligence tools for radiology, in a move aimed at expanding the use of autonomous AI in clinical imaging workflows.

Founded in 2017, Oxipit develops CE-marked AI software designed for radiology departments. Its best-known product, ChestLink, analyzes chest X-rays and can automatically identify exams that are highly likely to be normal. Those cases can be removed from the radiologist’s worklist, allowing clinicians to focus on studies that require closer review.

ChestLink received CE Class IIb certification, positioning it as an autonomous AI system for chest X-ray triage. The company has also begun extending its technology beyond chest imaging, adding tools for chest CT and musculoskeletal X-ray analysis.
“This is an important step in Oxipit’s journey,” said Peter Corscadden, CEO of Oxipit. “Sectra’s global footprint, strong clinical partnerships, and deep integration into radiology workflows create a powerful platform to responsibly scale autonomous AI. Together, we can accelerate access to AI solutions that fit naturally into daily reporting practice.”

Sectra, headquartered in Linköping, Sweden, develops enterprise imaging and IT systems used by healthcare organizations worldwide. By bringing Oxipit into its portfolio, the company aims to integrate autonomous AI more closely into established radiology workflows and distribute the technology across its existing customer base.

Oxipit will continue operating as usual until the transaction closes. The company said existing customers and partners should expect continuity in product development, service, and support.

Sectra reported sales of SEK 3.24 billion for the 2024–2025 fiscal year, and maintains direct sales operations in 19 countries.

The deal is expected to close in March, pending customary conditions.

Artificial Intelligence Homepage